[{"id":"89ef141c-4c3c-4497-a2e5-d3109f055079","acronym":"Uplift","url":"https://clinicaltrials.gov/study/NCT03319628","created_at":"2021-01-18T16:23:39.736Z","updated_at":"2024-07-02T16:35:29.563Z","phase":"Phase 1/2","brief_title":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","source_id_and_acronym":"NCT03319628 - Uplift","lead_sponsor":"Mersana Therapeutics","biomarkers":" SLC34A2","pipe":" | ","alterations":" SLC34A2 expression","tags":["SLC34A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SLC34A2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • upifitamab rilsodotin (XMT-1536)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 523","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2023-11-10"}]